This is a Phase 1, single center, randomized, two-period crossover study in healthy male and female subjects designed to evaluate the relative bioavailability (BA) and safety at steady state of two formulations of nimodipine: GTX 104 (nimodipine for intravenous \[IV\] infusion; test formulation) and nimodipine oral capsules, RS (reference formulation).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cmax Day 1
Timeframe: Day 1 for the first dose (8:00 AM dose)
AUC (AUCDay 3, 0-24hr)
Timeframe: Day 3 from 8:00 AM to 8:00 AM from 0 to 24 hr